Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) announced on October 21, 2025 that it purchased an additional $200,000 of Ethereum (ETH), bringing its total ETH holdings to $2 million.

The acquisition was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify and strengthen its long‑term asset base through targeted digital asset investments.

CHICAGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has acquired an additional $200,000 worth of Ethereum (ETH), bringing the Company’s total investment in ETH to $2 million.

This purchase was executed under Cosmos Health’s previously announced $300 million digital assets facility, which underpins the Company’s strategy to broaden and strengthen its portfolio through targeted digital asset investments.

Greg Siokas, CEO of Cosmos Health, stated: “Reaching the $2 million milestone in our Ethereum investment marks another important step in our digital asset expansion strategy. We remain steadfast in our commitment to leveraging our $300 million financing facility to further diversify and enhance our long-term asset base.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

FAQ

How much Ethereum did Cosmos Health (COSM) buy on October 21, 2025?

Cosmos Health purchased an additional $200,000 of Ethereum on October 21, 2025.

What is Cosmos Health's total investment in Ethereum (ETH) after the October 21, 2025 purchase?

After the purchase, Cosmos Health's total investment in Ethereum is $2 million.

Under which financing facility did COSM execute the October 21, 2025 Ethereum purchase?

The purchase was executed under Cosmos Health's previously announced $300 million digital assets facility.

What reason did Cosmos Health give for increasing its Ethereum holdings?

The company said the purchase supports its strategy to broaden and strengthen its portfolio and diversify its long‑term asset base.

Does the October 21, 2025 announcement state how Cosmos Health will use the remaining capacity of the $300 million facility?

No; the announcement only states the facility underpins the company's strategy and does not specify future purchases or remaining capacity.

Who commented on Cosmos Health's Ethereum milestone in the October 21, 2025 notice?

Greg Siokas, CEO of Cosmos Health, commented on reaching the $2 million Ethereum milestone.